The following is a summary of “Inspiratory hyperoxia suppresses lung cancer metastasis through a MYC/SLC1A5-dependent metabolic pathway” published in the December 2022 issue of Respiratory by Liu et al.

A significant amount of focus has been directed toward the knowledge gap concerning the impact of inspiratory hyperoxia on the microenvironment of lung-specific tumors and the advancement of lung cancer. According to the findings of this study, hyperoxia during inspiration may hold a particular significance for the malignant phenotype of lung cancer cells. In both in vitro and in vivo studies, the effects of various oxygenation conditions on the proliferation, apoptosis, invasion, and migration of lung cancer cells were comprehensively studied. 

Their findings indicate that treatment with inspiratory hyperoxia (60% oxygen, 6 hours per day -1) not only does not have any effects that encourage the evolution of tumors but it also prevents lung cancer spread and increases the likelihood of long-term survival. In addition, by combining analyses of the transcriptome, the proteome, and the metabolome, researchers could determine that subjecting lung cancer cells to hyperoxia led to the induction of significant intracellular metabolic alterations.  

Investigators demonstrated that myelocytomatosis oncogene/secondary lymphoid-tissue chemokine(MYC/SLC1A5)-induced metabolic reprogramming and glutamine addiction is a novel mechanism that drives lung cancer metastasis and that this process can be effectively inhibited by the therapy of inspiratory hyperoxia. These findings are crucial to the debate on the risks, promises, and potential antitumor effects of inspiratory hyperoxia, particularly for patients who have lung cancer.